





























Link to publication record in King's Research Portal
Citation for published version (APA):
Webster, L. M., Gill, C., Seed, P. T., Bramham, K., Wiesender, C., Nelson-Piercy, C., ... Chappell, L. C. (2018).
Chronic hypertension in pregnancy: the impact of ethnicity and superimposed preeclampsia on placental,
endothelial and renal biomarkers. AMERICAN JOURNAL OF PHYSIOLOGY REGULATORY INTEGRATIVE
AND COMPARATIVE PHYSIOLOGY, 315(1), R36-R47. https://doi.org/10.1152/ajpregu.00139.2017
Citing this paper
Please note that where the full-text provided on King's Research Portal is the Author Accepted Manuscript or Post-Print version this may
differ from the final Published version. If citing, it is advised that you check and use the publisher's definitive version for pagination,
volume/issue, and date of publication details. And where the final published version is provided on the Research Portal, if citing you are
again advised to check the publisher's website for any subsequent corrections.
General rights
Copyright and moral rights for the publications made accessible in the Research Portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognize and abide by the legal requirements associated with these rights.
•Users may download and print one copy of any publication from the Research Portal for the purpose of private study or research.
•You may not further distribute the material or use it for any profit-making activity or commercial gain
•You may freely distribute the URL identifying the publication in the Research Portal
Take down policy
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing details, and we will remove access to
the work immediately and investigate your claim.
Download date: 05. Apr. 2019
Biomarker variation in chronic hypertensive pregnancy 
 
Chronic hypertension in pregnancy: the impact of ethnicity and 1 
superimposed preeclampsia on placental, endothelial and renal 2 
biomarkers 3 
Louise M Webster1, Carolyn Gill1, Paul T Seed1, Kate Bramham1, Cornelia Wiesender2, Catherine Nelson-Piercy1, Jenny E 4 
Myers3,4, and Lucy C Chappell1. 5 
Author contributions: LMW and LCC designed the study, with input from all other authors. LMW and CG processed 6 
and analysed the samples, in addition to writing the manuscript. PS conducted the statistical analysis with assistance 7 
from LMW, KB and LCC. CW, JEM and LCC were site investigators for the study. KB, CNP, JEM and LCC supervised and 8 
corrected the manuscript.   9 
1 Women’s Health Academic Centre, King’s College London, St Thomas’ Hospital, London SE1 7EH 10 
2 Department of Obstetrics and Gynaecology, Leicester Royal Infirmary, University Hospitals of Leicester NHS Trust, 11 
Leicester, UK, LE1 5WW 12 
3 Maternal & Fetal Health Research Centre, Division of Developmental Biology and Medicine, School of Medical 13 
Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester Academic Health Science 14 
Centre, Oxford Rd, Manchester, UK, M13 0JH 15 
4 St Mary’s Hospital, Central Manchester Foundation Trust, Manchester Academic Health Science Centre, Manchester, 16 
UK, M13 9PL 17 
Correspondence address: 18 
Division of Women’s Health, King’s College London, 10th floor North Wing, St Thomas’ Hospital, 19 
Westminster Bridge Road, London, UK, SE1 7EH 20 
Corresponding author Louise M Webster (louise.m.webster@kcl.ac.uk) 21 
Tel: +44 20 7188 3628  Fax: +44 20 7620 1227  22 
Downloaded from www.physiology.org/journal/ajpregu by ${individualUser.givenNames} ${individualUser.surname} (159.092.238.208) on March 22, 2018.
Copyright © 2018 American Physiological Society. All rights reserved.
Biomarker variation in chronic hypertensive pregnancy 
 
ABSTRACT 23 
Black ethnicity is associated with worse pregnancy outcomes in women with chronic hypertension.  Pre-24 
existing endothelial and renal dysfunction, and poor placentation may contribute but pathophysiological 25 
mechanisms underpinning increased risk are poorly understood. This cohort study aimed to investigate the 26 
relationship between ethnicity, superimposed pre-eclampsia and longitudinal changes in markers of 27 
endothelial, renal and placental dysfunction in women with chronic hypertension. Plasma concentrations of 28 
placental growth factor (PlGF), syndecan-1, renin, aldosterone, and urinary angiotensinogen:creatinine ratio 29 
(AGTCR), protein:creatinine ratio (PCR) and albumin:creatinine ratio (ACR) were quantified during pregnancy 30 
and postpartum in women with chronic hypertension. Comparisons of longitudinal biomarker 31 
concentrations were made using log-transformation and random effects logistic regression allowing for 32 
gestation. Of 117 women, superimposed preeclampsia was diagnosed in 21% (n=25), with 24% (n=6) having 33 
an additional diagnosis of diabetes. The cohort included 63 (54%) women who self-identified as of Black 34 
ethnicity. PlGF concentrations were 67% lower (95% CI -79% to -48%), and AGTCR, PCR and ACR were higher 35 
over gestation, in women with subsequent superimposed preeclampsia (compared to those without 36 
superimposed preeclampsia). PlGF <100 pg/mL at 20-23.9 weeks’ gestation predicted subsequent 37 
birthweight <3rd centile with 88% sensitivity (95% CI 47%-100%) and 83% specificity (95% CI 70%-92%). Black 38 
women had 43% lower renin (95% CI -58% to -23%) and 41% lower aldosterone (95%CI -45% to -15%) 39 
concentrations over gestation. Changes in placental (PlGF) and renal (AGTCR/PCR/ACR) biomarkers predated 40 
adverse pregnancy outcome.  Ethnic variation in the renin-angiotensin-aldosterone system exists in women 41 
with chronic hypertension in pregnancy and may be important in treatment selection.  42 
Key words: chronic hypertension, pregnancy, renin-angiotensin-aldosterone system, placental growth factor  43 
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INTRODUCTION  44 
Chronic hypertension is estimated to affect 3% of pregnancies(41, 42) and is associated with adverse 45 
maternal and perinatal outcome.(5, 6) A recent systematic review by Bramham and colleagues (2014) 46 
reported a relative risk of superimposed preeclampsia of 7.7 (95% confidence interval 5.7 to 10.1) compared 47 
to the risk of preeclampsia in the general pregnant population.(6) Adverse perinatal outcomes such as 48 
stillbirth, fetal growth restriction and prematurity are also more common in women with chronic 49 
hypertension and occur independently from a diagnosis of superimposed preeclampsia.(1, 13, 43) Women of 50 
Black ethnicity, compared to women of White ethnicity with chronic hypertension, have an increased risk of 51 
superimposed preeclampsia,(13) which may be contributory, but greater understanding of the interplay of 52 
known biomarkers and ethnicity in women with chronic hypertension may provide insight into 53 
pathophysiological mechanisms.     54 
 55 
Preeclampsia is characterized by placental and maternal vascular dysfunction.(44) Placental growth factor 56 
(PlGF) and syndecan-1 are placental and endothelial biomarkers that have previously been shown to 57 
decrease in concentration in the maternal circulation prior to the onset of the clinical signs of 58 
preeclampsia.(23, 30, 31) A recent study by Chappell and colleagues (2013) has demonstrated that low PlGF, 59 
in women presenting before 35 weeks’ gestation with suspected preeclampsia, has high sensitivity and 60 
negative predictive value for preeclampsia within 14 days.(12) Diagnosing superimposed preeclampsia in 61 
women with chronic hypertension is challenging because gestational progression of hypertension may occur 62 
in response to the physiological changes in pregnancy, without the sequelae of preeclampsia. Variation in 63 
these biomarkers over gestation in women with chronic hypertension requires further exploration. 64 
  65 
The kidney is of critical importance in blood pressure regulation primarily via salt and water homeostasis. A 66 
key mechanism underpinning this homeostatic function is the role of the kidney in the systemic renin-67 
angiotensin-aldosterone system (RAAS). Increased glomerular filtration and upregulation of the circulating 68 
RAAS are amongst the physiological changes that characterise normotensive pregnancy.(17, 19) Changes in 69 
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the RAAS and other renal biomarkers (protein: creatinine ratio (PCR) and albumin: creatinine ratio (ACR)) 70 
have been demonstrated in preeclampsia;(7, 15) however there are limited data from longitudinal cohorts 71 
examining these biomarkers in pregnant women with chronic hypertension.(4) The impact of ethnicity on 72 
these biomarkers in pregnancy also requires exploration. Black women are more likely to have low renin 73 
hypertension(40) and ethnic differences in RAAS function in pregnancy may partly explain disparity observed 74 
in clinical outcome.(8, 38)  75 
 76 
This study aimed to investigate the longitudinal variation in endothelial and renal biomarkers in women with 77 
chronic hypertension in pregnancy, and the impact of subsequent superimposed preeclampsia and ethnicity 78 
on these biomarkers.  79 
 80 
GLOSSARY 81 
AGTCR  Angiotensinogen: creatinine ratio 82 
ACR  Albumin: creatinine ratio 83 
CHT  Chronic hypertension 84 
ELISA  Enzyme-linked immunosorbent assay 85 
GROW  Gestation adjusted optimal weight 86 
NHS   National Health Service 87 
PCR  Protein: creatinine ratio 88 
PlGF  Placental growth factor 89 
RAAS  Renin-angiotensin-aldosterone system (systemic) 90 
RAS  Renin-angiotensin system (organ-specific) 91 
SPE  Superimposed preeclampsia  92 
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MATERIALS AND METHODS 93 
This was a nested cohort study of women with chronic hypertension who participated in the ‘Pregnancy And 94 
chronic hypertension: NifeDipine vs lAbetalol as antihypertensive treatment’ trial between 2014 and 2016. 95 
The study was registered with ISRCTN (DOI 10.1186/ISRCTN40973936, www.isrctn.com) and approved by 96 
the UK Research Ethics Committee (REC number 13/EE/0390). The primary results of the randomised 97 
controlled trial and the mechanistic comparison of antihypertensive treatment has been presented 98 
elsewhere.(48) This cohort study was reported in line with STROBE guidance for observational studies.(20)  99 
 100 
Study Design 101 
Women were enrolled at three consultant-led National Health Service (NHS) obstetric units in the United 102 
Kingdom (Guy’s and St Thomas’ NHS Foundation Trust (London), Central Manchester University NHS 103 
Foundation Trust (Manchester), and University of Leicester Hospitals NHS Trust (Leicester)). The eligibility 104 
criteria included: women with a prenatal diagnosis of chronic hypertension or blood pressure readings 105 
≥140/90 mm Hg at least four hours apart prior to 20 weeks’ gestation requiring antihypertensive treatment, 106 
(as defined by the International Society for the Study of Hypertension in Pregnancy classification of 107 
hypertensive disorders of pregnancy(47)) between 12 and 27.9 weeks’ gestation, singleton pregnancies, 108 
aged over 18 years, and the ability to provide informed consent. No formal power calculation was 109 
performed, but all women participating in the main trial at the sites afore mentioned, were asked to 110 
participate in the sub-study. Participants were asked to provide longitudinal samples of blood and urine at 111 
study entry and at follow-up antenatal visits across gestation and at six weeks postpartum. Baseline 112 
demographic and antenatal booking data were collected at enrollment. Ethnicity (Black versus non-Black) 113 
was determined by self-report of a parent or grandparent who was African/Caribbean (Black ethnicity) or 114 
not (non-Black ethnicity, which included women of European and Asian family origin). Blood pressure 115 
readings taken at all subsequent antenatal visits and daily during hospital admissions  were recorded in 116 
addition to other maternal and perinatal outcome data (superimposed preeclampsia, mode of delivery, 117 
gestation at delivery, pregnancy loss, birthweight, birthweight centile and neonatal unit admission). The 118 
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diagnosis of superimposed preeclampsia utilised the definitions from the American Congress of Obstetrics 119 
and Gynaecology;(37) the diagnosis was confirmed by two clinicians and was either defined as chronic 120 
hypertension with new-onset proteinuria in those without chronic kidney disease or a sudden increase in 121 
proteinuria in those with chronic kidney disease, and an increase in hypertension. Women with PCR >30 122 
mg/mmol at study entry (likely indicative of chronic kidney disease) were excluded from the analysis of 123 
urinary biomarkers. Customised birthweight centiles were calculated using the GROW formula with 124 
adjustment for maternal height, maternal weight, maternal ethnicity, parity, infant sex, infant birthweight 125 
and gestation at birth (version 6.7.5.1 (2014)).(24) An international consensus statement has now 126 
determined that birthweight below the 3rd centile represents fetal growth restriction and birthweight below 127 
the 10th centile represents small for gestational age.(25)  128 
 129 
Analysis of Samples 130 
Venous blood and midstream urine samples were placed on ice immediately after collection, spun at 1400xg 131 
for 10 minutes and stored at -80 ֯C within four hours. The following tests were conducted without knowledge 132 
of clinical outcomes. 133 
Placental and endothelial biomarkers: Plasma PlGF and plasma syndecan-1 concentrations were measured 134 
on all antenatal samples. PlGF was quantified using the Triage PlGF Test (Alere, San Diego, USA) according to 135 
the manufacturer’s instructions.(12) Syndecan-1 concentrations were measured using a solid phase 136 
sandwich ELISA kit for quantification of human syndecan-1 (Abnova, Taipei City, Taiwan), in accordance with 137 
manufacturer’s instructions.(45) 138 
Renal biomarkers: Plasma renin and aldosterone concentration, and urinary AGTCR, PCR, and ACR were 139 
quantified for all samples (antenatal and postpartum). Plasma renin and aldosterone were measured using 140 
Diasorin Liaison direct renin and aldosterone reagents respectively (Diasorin, Wokingham, UK), run on the 141 
Liaison chemiluminescence analyser.(9)  142 
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Urinary angiotensinogen concentrations were determined using a solid phase sandwich ELISA kit (Immuno-143 
Biological Laboratories, Gunma, Japan) according to manufacturer’s instructions.(27) The urinary 144 
angiotensinogen concentrations were then normalised to urinary creatinine to provide AGTCR. Urinary 145 
creatinine, protein and albumin reagents were supplied by Siemens Healthcare Diagnostics Ltd (Camberley, 146 
UK). Urinary creatinine reacted with picric acid under alkaline conditions to form a red Janovsky complex 147 
(the Jaffé reaction).(34) The initial rate of absorbance change was measured at a wavelength of 505 nm and 148 
compared to that of a known calibrant. This was directly proportional to the concentration of creatinine in 149 
the sample. A blank reaction rate was performed using reagent 1 (sodium hydroxide, before picrate 150 
addition) to minimise interference from bilirubin. Urinary protein forms a blue coloured complex with 151 
pyrogallol red, under acid conditions and in the presence of molybdate ions.(22) The absorbance of this 152 
complex was measured at 596 nm, and related to that of a previous calibration assay. Urine albumin was 153 
measured using a polyethylglycol enhanced immunoturbidimetric method a commonly used assay 154 
technique.(10) The sample was diluted and then reacted with antiserum to form a precipitate that was 155 
measured turbidimetrically at 340nm. Urine albumin was measured on the Siemens Advia 2400 analyser.  156 
 157 
Statistical Analysis 158 
The statistical software Stata version 14 (StataCorp, College Station, Texas) and GraphPad Prism 7 (Graph 159 
Pad Software, San Diego, California) were used for all analyses. The investigation was divided into two parts. 160 
Analysis A compared baseline characteristics, clinical outcomes and endothelial and renal biomarkers 161 
between women with chronic hypertension who subsequently developed superimposed preeclampsia and 162 
women with chronic hypertension who did not develop superimposed preeclampsia during their pregnancy. 163 
Analysis B compared baseline characteristics, clinical outcomes and endothelial and renal biomarkers 164 
between women with chronic hypertension self-identifying as of Black ethnicity with women with chronic 165 
hypertension self-identifying as of non-Black ethnicity. An additional analysis examined the relationship 166 
between each biomarker and birthweight centile. Baseline characteristics and clinical outcomes were 167 
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compared between subgroups in analyses A and B using t-tests or Mann-Whitney test for continuous 168 
variables depending on the distributions and Fisher’s exact test for categorical variables. Mean post-169 
enrollment systolic and diastolic blood pressure were calculated using the trapezium method of analysing 170 
the area under the curve for each woman. Variation in longitudinal endothelial and renal biomarkers for 171 
analyses A and B was assessed using random effects GLS regression with robust standard errors(3)  on log-172 
transformed data allowing for gestation effects. Logged estimates with 95% confidence intervals of the 173 
geometric means and of their ratios to the reference group in each analysis were calculated. Standard 174 
mathematic methods converted these to percentage differences between groups: percent difference = 175 
(exp[parameter]– 1) x 100%. An interaction test examining the correlation between ethnicity, diagnosis of 176 
superimposed preeclampsia and gestation was performed using a random-effects regression model, 177 
wherever significant ethnic differences in biomarker concentration were demonstrated. 178 
 179 
RESULTS 180 
The cohort recruited to the study included 121 women with singleton pregnancies and chronic hypertension 181 
(Figure 1). Longitudinal samples (332 in total) were obtained in 117 (97%) women; outcome data were 182 
unavailable for four (3.3%) women (two women lost to follow-up and two withdrew from the study). For 183 
analysis A, the cohort was divided into women diagnosed with superimposed preeclampsia and compared 184 
with women who were not diagnosed with superimposed preeclampsia (n=25 versus n=92) and for analysis 185 
B, the cohort was divided into women self-identifying as of Black ethnicity versus women self-identifying as 186 
of non-Black ethnicity (n=63 versus n=54).     187 
 188 
The baseline demographics of the women who provided samples for the analyses are detailed in Table 1. 189 
The women who developed superimposed preeclampsia, compared to those who did not, were younger (33 190 
years versus 36 years; p 0.04), and a higher proportion of the women who developed superimposed 191 
preeclampsia, compared to those who did not, had pre-existing diabetes mellitus (24% versus 6.5%; p 0.02). 192 
Fewer black women were nulliparous, compared to non-Black women (6.3% versus 33%; p 0.0003), and the 193 
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diastolic blood pressure was higher in Black women than non-Black women at antenatal booking (88 mmHg 194 
versus 85 mmHg; p 0.03). Otherwise the groups were comparable at baseline. 195 
 196 
Maternal and perinatal outcomes for the cohort as a whole, in addition to the subgroups within analysis A 197 
(superimposed preeclampsia versus chronic hypertensive controls) and B (Black women versus non-Black 198 
women), are shown in Table 2 and 3. There were no differences in outcome between labetalol and 199 
nifedipine arms of the trial. Superimposed preeclampsia was diagnosed in 21% (n=25) of the whole cohort of 200 
women with chronic hypertension, with 31% (n=36) of infants being born before 37 weeks’ gestation and 201 
91% (n=106) livebirths. Of the 106 livebirths, 29% (n=31) had a birthweight below the 10th centile (n=18 of 202 
these infants were born before 37 weeks’ gestation), 15% (n=16) had a birthweight below the 3rd centile, and 203 
23% (n=25) required admission to the neonatal unit.  204 
 205 
Within the subgroups, the greatest differences in maternal and perinatal outcome were seen in the women 206 
with chronic hypertension who developed superimposed preeclampsia compared to chronic hypertensive 207 
controls. The mean systolic (137 mmHg versus 132 mmHg; p 0.005) and mean diastolic (87 mmHg versus 84 208 
mmHg; p 0.002) blood pressures were higher in the women with superimposed preeclampsia compared to 209 
those with no superimposed preeclampsia. Women diagnosed with superimposed preeclampsia were more 210 
likely to have an emergency Caesarean birth, compared to those without superimposed preeclampsia (64% 211 
versus 42%; p 0.03). Additionally, preterm birth before 37 weeks’ gestation occurred more frequently in 212 
women with superimposed preeclampsia than without (56% versus 24%; p 0.003). The infants born to 213 
mothers who were diagnosed with superimposed preeclampsia, compared to those who were not, had 214 
lower birthweights (2270g versus 3020g; p <0.0001) and were more likely to be admitted to the neonatal 215 
unit (52% versus 14%; p 0.0007). The only significant difference in maternal and perinatal outcome found 216 
between the women of Black ethnicity and those of non-Black ethnicity, was higher mean post-enrollment 217 
diastolic blood pressure (Black women: 86 mmHg versus non-Black women: 83 mmHg; p 0.03). 218 
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 219 
Endothelial biomarkers 220 
 The longitudinal changes in PlGF and syndecan-1 are displayed in Figures 2, 3 and 4. Analysis A 221 
(superimposed preeclampsia versus no superimposed preeclampsia) demonstrated that PlGF concentration 222 
increased across gestation in the women who did not develop SPE to a peak mean value of 363 pg/mL at 28 223 
to 31.9 weeks’ gestation, but in the women who developed subsequent SPE the peak mean PlGF was 105 224 
pg/mL and occurred at 20 to 23.9 weeks’ gestation (Figure 2).Comparative analysis demonstrated that the 225 
PlGF concentrations were 67% lower (95% confidence interval -79% to -48%; p=<0.001) in women who 226 
developed superimposed preeclampsia compared to those who did not. In analysis B, PlGF concentration 227 
increased across gestation in women of Black ethnicity and women of non-Black ethnicity (Figure 2). There 228 
was no overall difference in concentrations between groups (-2%; 95% confidence interval -43% to 68%; 229 
p=0.94). 230 
 231 
Given the high proportion of infants born below the 3rd and 10th centile in this cohort of women with chronic 232 
hypertension, an additional analysis assessed the gestational changes in each biomarker and birthweight 233 
centile. The only biomarker demonstrating a significant association with birthweight centile category (<3rd, 234 
3rd to 10th and >10th) was PlGF (Figure 3). PlGF <100 pg/mL at 20 to 23.9 weeks’ gestation to predict 235 
subsequent birthweight <3rd centile demonstrated 88% sensitivity (95% confidence interval 47% to 100%), 236 
83% specificity (95% confidence interval 70% to 92%), and the negative predictive value was 98% (95% 237 
confidence interval 88% to 100%).   238 
 239 
Syndecan-1 concentrations increased significantly across gestation in all subgroups (p <0.0001) (Figure 4). 240 
Postpartum syndecan-1 concentrations were 83% lower (95% confidence interval -87% to -78%; p=<0.001) 241 
than antenatal syndecan-1 concentrations. No significant differences were found in syndecan-1 242 
concentrations either in women with chronic hypertension who did and did not develop superimposed 243 
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preeclampsia (-5%; 95% confidence interval -24% to 18%; p=0.62), or in women with chronic hypertension of 244 
Black or non-Black ethnicity (-5%; 95% confidence interval -22% to 15%; p=0.59).  245 
 246 
Renal biomarkers 247 
Plasma renin concentrations did not vary significantly over the gestation studied (12 to 35.9 weeks) (Figure 248 
5); however antepartum renin concentrations were significantly higher than in samples taken six weeks 249 
postpartum (p <0.0001). In the women who developed superimposed preeclampsia, the mean renin 250 
concentrations at each gestational time point tended to be higher than in women who did not develop 251 
superimposed preeclampsia until 32 to 35.9 weeks’ gestation. However, these differences were not 252 
statistically significant when longitudinal measures were compared (34%; 95% confidence interval -2% to 253 
82%; p=0.06). In Black women with chronic hypertension with or without superimposed preeclampsia, the 254 
mean renin concentrations were significantly lower across gestation compared to women of non-Black 255 
ethnicity (-43%; 95% confidence interval -58% to -23%; p=<0.001). Further analysis explored the differences 256 
between gestational renin concentrations and six-week postpartum renin concentrations. In women of Black 257 
ethnicity, postpartum renin concentrations were 81% lower (95% confidence interval -91% to -58%; 258 
p=<0.001) compared with antenatal concentrations and in non-Black women the postpartum renin 259 
concentrations were 54% lower (95% confidence interval -73% to -22%; p=0.004) than antenatal values in 260 
this group. An interaction test examined the potential relationship between ethnicity, gestation and 261 
diagnosis of superimposed preeclampsia and did not demonstrate a significant correlation.  262 
 263 
Aldosterone concentrations were 57% higher (95% confidence interval 43% to 68%; p=<0.001) in pregnancy 264 
than at six weeks postpartum. No significant difference was found in aldosterone concentrations between 265 
the women who did and did not develop superimposed preeclampsia (5%; 95% confidence interval -20% to 266 
39%; p=0.73) (Figure 6). In the women of Black ethnicity compared to those of non-Black ethnicity who did 267 
or did not develop superimposed preeclampsia, aldosterone concentrations in pregnancy were 31% lower 268 
(95% confidence interval -45% to -15%; p=0.001). There was no difference in aldosterone concentrations 269 
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between ethnic groups at the six-week postpartum timepoint (13%; 95% confidence interval -46% to 131%; 270 
p=0.72). Across gestation, aldosterone concentrations increased by 70% in the women of non-Black ethnicity 271 
(95% confidence interval 39% to 209%; p=<0.001); however in the Black women no significant increase in 272 
aldosterone concentrations was demonstrated across gestation (13%; 95% confidence interval -7% to 37%; 273 
p=0.23). An interaction test explored the potential association of ethnicity, gestation and diagnosis of 274 
superimposed preeclampsia and did not demonstrate a significant correlation. Aldosterone: renin ratio was 275 
calculated and compared for analysis A and B, but no association was seen. 276 
 277 
Women with chronic kidney disease were excluded from the analysis of the urinary biomarkers (n=11). 278 
Urinary AGTCR increased across gestation and was significantly lower at six weeks postpartum (-79%; 95% 279 
confidence interval -86% to -69%; p=<0.001). In the women with superimposed preeclampsia, compared to 280 
chronic hypertensive controls, the AGTCR was 63% higher across gestation (95% confidence interval 10% to 281 
142%; p=0.02) (Figure 7). There was no difference between the AGTCR in women of Black or non-Black 282 
ethnicity (12%; 95% confidence interval -22% to 61%; p=0.53). No correlation between the systemic RAAS 283 
(plasma renin and aldosterone) or the intra-renal RAS (AGTCR) was found. 284 
 285 
PCR increased across gestation in all subgroups (51%; 95% confidence interval 24% to 84%; p=<0.001) and 286 
returned to levels comparable to the 12 to 16.9 week mean ratio by six weeks postpartum. PCR was overall 287 
significantly higher across gestation in the women who subsequently developed superimposed preeclampsia 288 
compared to those who did not (29%; 95% confidence interval 5% to 57%; p=0.01) (Figure 8). There was no 289 
significant difference in PCR across gestation in Black and non-Black women (4%; 95% confidence interval -290 
14% to 24%; p=0.71).  291 
 292 
ACR did not vary significantly across gestation in the cohort as a whole (20%; 95% confidence interval -10% 293 
to 59%; p=0.22). However, in the women who were subsequently diagnosed with superimposed 294 
preeclampsia compared to chronic hypertensive controls, ACR was higher (123%; 95% confidence interval 295 
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67% to 197%; p=<0.001) (Figure 9). There was no difference in ACR when women of Black and non-Black 296 
ethnicity were compared (10%; 95% confidence interval -19% to 50%; p=0.55). 297 
 298 
DISCUSSION 299 
This study has confirmed that low PlGF across gestation in women with chronic hypertension in pregnancy 300 
predates the clinical presentation of superimposed preeclampsia and fetal growth restriction. To our 301 
knowledge, this is the first study in women with chronic hypertension to demonstrate the potential utility of 302 
PlGF as a predictive tool for fetal growth restriction; with further validation, PlGF concentrations <100 pg/mL 303 
at 20 to 23.9 weeks’ gestation may aid risk stratification and timing of ultrasound surveillance in this group. 304 
Furthermore, the potential utility of PlGF in the diagnosis and prediction of superimposed preeclampsia in 305 
women with chronic hypertension, a group in whom the diagnosis is most challenging given the pre-existing 306 
hypertension, is demonstrated. Low PlGF concentrations across gestation in women who develop 307 
preeclampsia has been demonstrated in women without chronic hypertension.(31) It has been proposed 308 
that the imbalance in angiogenic markers observed in women with preeclampsia was greater than observed 309 
in women with superimposed preeclampsia,(14) but the findings of our study support comparable 310 
pathophysiology underpinning preeclampsia in women with and without chronic hypertension and reported 311 
elsewhere.(35)    312 
 313 
The high incidence of adverse maternal and perinatal outcomes in women with chronic hypertension in 314 
pregnancy is highlighted by this study with 21% of women developing superimposed preeclampsia, 315 
comparable with the findings of other studies ranging from 17 to 25%.(33, 39, 41, 42) The incidence of 316 
superimposed preeclampsia is this cohort may relate in part to the number of participants with diabetes, as 317 
demonstrated by the significant difference in the proportion of women with diabetes and chronic 318 
hypertension that developed superimposed preeclampsia compared to those who did not (24% versus 6.5%; 319 
p 0.02). Women with chronic hypertension who did not develop superimposed preeclampsia were also at 320 
increased risk of adverse perinatal outcome compared to background incidence, but a significantly greater 321 
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proportion of adverse perinatal outcomes were seen in the women who developed superimposed 322 
preeclampsia.  323 
 324 
Syndecan-1 is a transmembrane heparin sulphate proteoglycan expressed on the extracellular, luminal 325 
surface of epithelial cells and syncytiotrophoblasts, forming part of the glycocalyx of these cells. Syndecan-1 326 
is involved in the regulation of cell adhesion, proliferation, motility, intra-cellular signalling and 327 
angiogenesis.(46) Our findings confirm circulating syndecan-1 concentrations increase across gestation as 328 
previously demonstrated;(23) however in this study syndecan-1 concentrations did not differ significantly in 329 
women with chronic hypertension who developed subsequent superimposed preeclampsia compared with 330 
chronic hypertensive controls. This finding is in contrast to results reported by Gandley and colleagues 331 
(2016) who reported that plasma syndecan-1 concentrations at 20 weeks’ gestation were significantly lower 332 
in women who developed subsequent preeclampsia (174 ng/mL versus 272 ng/mL; p <0.05).(23) These 333 
differences may relate to differing pathophysiology underpinning preeclampsia in women with chronic 334 
hypertension compared to women without chronic hypertension; although the relative contributions of 335 
angiogenic imbalance and other factors is uncertain, these results support low PlGF concentrations having a 336 
better association with subsequent disease rather than syndecan-1.(14) Further exploration of the role of 337 
syndecan-1 in the pathophysiology of placental disease in different populations is required to determine the 338 
clinical utility of this biomarker. 339 
 340 
The role of the systemic RAAS in the pathophysiology of placental disease in women with chronic 341 
hypertension in pregnancy is unclear. No significant variations in plasma renin or aldosterone concentrations 342 
were found across gestation in the women who did and did not develop superimposed preeclampsia; this 343 
may be driven by the expected Angiotensin II inhibitory feedback on renin release, which is independent of 344 
angiotensinogen substrate production. Women with preeclampsia demonstrate greater sensitivity to 345 
Angiotensin II, compared with normotensive pregnant women; it is possible the cellular RAS pathway 346 
through which the increased sensitivity is demonstrated, is independent of systemic substrates.(29) Previous 347 
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studies have demonstrated that the RAAS is upregulated in normotensive pregnancy and our study confirms 348 
that this upregulation occurs in both the Black and non-Black women with chronic hypertension, though it is 349 
unclear if this is in response to, or the cause of other physiological changes that occur in pregnancy such as 350 
increased plasma volume and vasodilation.(2) Brown and colleagues (1997) performed a cross-sectional 351 
study and found that women diagnosed with preeclampsia had lower plasma concentrations of renin and 352 
aldosterone compared to normotensive pregnant women.(7) Another longitudinal study by August and 353 
colleagues (1990) in 25 pregnant women with chronic hypertension, demonstrated reduced plasma renin 354 
activity and lower urinary aldosterone concentrations in those who developed subsequent superimposed 355 
preeclampsia compared to those who did not.(4)  Importantly our study confirms that systemic renin and 356 
aldosterone concentrations in Black women with chronic hypertension are lower across gestation compared 357 
to non-Black women in keeping with the non-pregnant state, and any future investigation of the role of the 358 
systemic RAAS in pregnancy should account for this ethnic variation. 359 
 360 
It is interesting that although there is variation in the systemic RAAS between ethnic groups, no variation in 361 
the intrarenal RAS was observed, nor was any relationship between systemic and intrarenal identified. 362 
Increased urinary AGTCR were found across gestation in women who developed superimposed preeclampsia 363 
compared to those who did not. Pathological upregulation of the intrarenal RAS in preeclampsia would be 364 
consistent with findings outside pregnancy; an activated intrarenal RAS has been reported in the progression 365 
of renal injury in diabetic and membranous nephropathy.(28) However, our findings do not agree with a 366 
cross-sectional study reported by Yilmaz and colleagues (2009), who compared time-of-disease AGTCR in 30 367 
women with preeclampsia with 30 normotensive pregnant women. They found that urinary AGTCR were 368 
lower in women with preeclampsia,(49) which may represent variation specific to their sample. This study 369 
did, however, report a positive correlation between urinary AGTCR, high blood pressure and proteinuria, and 370 
concluded that ‘local RAS activation in the kidneys may be one of the contributing factors in the 371 
development of preeclampsia’.(49) In this respect our findings concur, but further investigation is required 372 
to establish the importance of the intrarenal RAS in the pathophysiology of superimposed preeclampsia.    373 
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 374 
PCR and ACR were higher across gestation in women with chronic hypertension who developed subsequent 375 
superimposed preeclampsia compared to those who did not. This may represent underlying nephropathy in 376 
this group of women with chronic hypertension, as described by Crews and colleagues (2010).(16) However, 377 
another study by Poon and colleagues (2008) found higher first trimester ACR was associated with 378 
subsequent development of preeclampsia,(36) so it may be that the association of higher PCR/ACR from the 379 
first trimester is indicative of endothelial dysfunction with subsequent development of superimposed 380 
preeclampsia. The clinical utility of these findings are unclear, as proteinuria is known to increase in 381 
normotensive pregnancy and identifying when protein excretion is abnormal is problematic.(18, 32) It is also 382 
notable that the mean PCR and ACR values across gestation in the women in our cohort who developed 383 
subsequent superimposed preeclampsia were below 30 mg/mmol and 8 mg/mmol respectively (prior to 384 
diagnosis), which are currently utilised for clinical diagnosis.(47)  385 
 386 
In this study, the proportion of the Black women developing superimposed preeclampsia was lower than the 387 
proportion of non-Black women (14% versus 30%; p=0.07), though this was not significant and may relate in 388 
part to the higher proportion of multiparous women in the Black group. The significant difference in booking 389 
and mean post-enrollment diastolic blood pressures in women of Black ethnicity, compared to non-Black, 390 
suggests potential ethnic variation in disease severity, which has been demonstrated in the non-pregnant 391 
population.(11, 21, 26) Variation in the systemic RAAS may play a role in ethnic disparity in disease severity; 392 
the incidence of SPE in Black women is lower within this cohort compared to the increased incidence of SPE 393 
in Black women observed in other cohorts and this may have had an impact on the findings of these 394 
analyses. Our study has highlighted differences in the RAAS, in particular a third trimester increase in 395 
aldosterone concentrations that is present in the non-Black women, but not in the Black women and these 396 
findings warrant further exploration. 397 
 398 
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The strengths of this study include multicentre recruitment of a wide ethnic mixture of women with chronic 399 
hypertension in pregnancy. Longitudinal sampling has allowed assessment of variation of biomarkers across 400 
gestation prior to development of adverse outcome. In contrast, a limitation of the study was the absence of 401 
time-of-disease sampling, preventing comparison of each biomarker at the time of clinical diagnosis of 402 
superimposed preeclampsia, and the findings of this study would require validation in a much larger cohort. 403 
The high proportion of women with diabetes in this cohort may also have impacted the results of analysis A 404 
and it is not possible to fully elucidate the potential impact of hyperglycaemia on our findings. Additionally, 405 
although some participants may have had white coat hypertension, 24-hour ambulatory monitoring is not 406 
routinely performed during pregnancy and would usually only have been confirmed after pregnancy. Future 407 
research should aim to examine longitudinal and time of disease biomarker concentrations, with 408 
simultaneous quantification of other biomarkers that are involved in pathophysiological pathways such as 409 
the RAAS. This would provide further explanation of the mechanisms underpinning increased adverse 410 
maternal and perinatal outcome in pregnant women with chronic hypertension.  411 
 412 
PERSPECTIVES AND SIGNIFICANCE 413 
The incidence of chronic hypertension in pregnancy is increasing with rising maternal age and obesity. The 414 
prevalence of chronic hypertension in women aged below 50 years is greater in those of Black ethnicity, 415 
compared to other ethnicities. Adverse maternal and perinatal outcomes are associated with chronic 416 
hypertension and the mechanisms behind these increased risks are poorly understood. In this study, changes 417 
in placental and renal biomarkers predate development of superimposed preeclampsia. Low plasma PlGF 418 
has a strong association with subsequent fetal growth restriction in women with chronic hypertension and 419 
ethnic variation in RAAS biomarkers may relate to disparity in outcome. Further research into the physiology 420 
underpinning these differences is warranted. 421 
 422 
  423 
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FIGURE LEDGENDS: 573 
 574 
Figure 1 Overview flow of study participants including grouping for analyses A and B 575 
CHT= chronic hypertension, SPE=superimposed preeclampsia  576 
 577 
Figure 2 Placental growth factor concentrations across gestation in pregnant women with chronic 578 
hypertension. Lower limit of detection=12pg/mL. Comparison A: superimposed preeclampsia (SPE) versus no 579 
SPE. Comparison B: women of Black ethnicity versus non-Black ethnicity Variation in longitudinal PlGF 580 
concentration for analyses A and B was assessed using random effects GLS regression with robust standard 581 
errors on log-transformed data allowing for gestation effects. 582 
 583 
Figure 3 Placental growth factor concentration and infant birthweight centile. Lower limit of 584 
detection=12pg/mL.    585 
A: Placental growth factor across gestation in pregnant women with chronic hypertension divided by 586 
birthweight centile categories (measured using random effects GLS regression with robust standard errors on 587 
log-transformed data allowing for gestation effects) 588 
B: Box plot of placental growth factor concentration at 20 to 23.9 weeks and 24 to 29.9 weeks’ gestation 589 
divided by infant birthweight centile category 590 
 591 
Figure 4 Syndecan-1 concentrations across gestation in pregnant women with chronic hypertension. 592 
Comparison A: superimposed preeclampsia (SPE) versus no SPE. Comparison B: women of Black ethnicity 593 
versus non-Black ethnicity. Variation in longitudinal Syndecan-1 concentration for analyses A and B was 594 
assessed using random effects GLS regression with robust standard errors on log-transformed data allowing 595 
for gestation effects. 596 
  597 
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Figure 5 Renin concentrations across gestation in pregnant women with chronic hypertension. Comparison A: 598 
superimposed preeclampsia (SPE) versus no SPE. Comparison B: women of Black ethnicity versus non-Black 599 
ethnicity. Variation in longitudinal Renin concentration for analyses A and B was assessed using random 600 
effects GLS regression with robust standard errors on log-transformed data allowing for gestation effects. 601 
 602 
Figure 6 Aldosterone concentrations across gestation in pregnant women with chronic hypertension. 603 
Comparison A: superimposed preeclampsia (SPE) versus no SPE. Comparison B: women of Black ethnicity 604 
versus non-Black ethnicity. Variation in longitudinal Aldosterone concentration for analyses A and B was 605 
assessed using random effects GLS regression with robust standard errors on log-transformed data allowing 606 
for gestation effects. 607 
 608 
Figure 7 Urinary angiotensinogen: creatinine concentrations across gestation in pregnant women with 609 
chronic hypertension. Comparison A: superimposed preeclampsia (SPE) versus no SPE. Comparison B: women 610 
of Black ethnicity versus non-Black ethnicity. Variation in longitudinal urinary angiotensinogen: creatinine 611 
ratio for analyses A and B was assessed using random effects GLS regression with robust standard errors on 612 
log-transformed data allowing for gestation effects. Women with chronic kidney disease were excluded from 613 
these analyses. 614 
 615 
Figure 8 Urinary protein: creatinine ratio concentrations across gestation in pregnant women with chronic 616 
hypertension. Comparison A: superimposed preeclampsia (SPE) versus no SPE (samples taken prior to the 617 
diagnosis of superimposed preeclampsia). Comparison B: women of Black ethnicity versus non-Black 618 
ethnicity. Variation in longitudinal urinary protein: creatinine ratio for analyses A and B was assessed using 619 
random effects GLS regression with robust standard errors on log-transformed data allowing for gestation 620 
effects. Women with chronic kidney disease were excluded from these analyses. 621 
 622 
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Figure 9 Urinary albumin: creatinine ratio concentrations across gestation in pregnant women with chronic 623 
hypertension. Comparison A: superimposed preeclampsia (SPE) versus no SPE (samples taken prior to the 624 
diagnosis of superimposed preeclampsia). Comparison B: women of Black ethnicity versus non-Black 625 
ethnicity. Variation in longitudinal urinary albumin: creatinine ratio for analyses A and B was assessed using 626 
random effects GLS regression with robust standard errors on log-transformed data allowing for gestation 627 
effects. Women with chronic kidney disease were excluded from these analyses.  628 
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TABLES: 629 
Table 1 Baseline demographics for the cohort 630 













Age at study entry, years 
mean (SD) 
35 (5) 33* (6) 36 (5) 36 (5) 35 (6) 
Body mass index, Kg/m2 
mean (SD) 
31 (6.2) 31 (5.8) 31 (6.3) 32 (5.5) 30 (6.9) 
Nulliparity 
number (%) 
22 (19%) 7 (28%) 15 (16%) 4* (6.3%) 18 (33%) 
Smoker 
number (%) 
1 (0.9%) 0 1 (1.1%) 0 1 (1.9%) 
Booking blood pressure, mmHg 
median (IQR) 
     
Systolic 
135 
(126 to 142) 
134 
(127 to 140) 
136 
(126 to 142) 
139 
(126 to 147) 
134 
(126 to 140) 
Diastolic 
88 
(81 to 92) 
85 
(82 to 90) 
88 
(81 to 92) 
88* 
(84 to 96) 
85 
(80 to 90) 
Renal disease 
number (%) 
10 (8.5%) 3 (12%) 7 (7.6%) 4 (6.3%) 6 (11%) 
Diabetes mellitus 
number (%) 
12 (10%) 6* (24%) 6 (6.5%) 7 (11%) 5 (9.3%) 
Centre      
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number (%) 
Guy’s and St Thomas’ NHS 
Foundation Trust 
73 (62%) 10 (40%) 64 (70%) 48 (76%) 25 (46%) 
Central Manchester University 
Hospitals NHS Foundation Trust 
29 (25%) 8 (32%) 21 (23%) 13 (21%) 16 (30%) 
University Hospitals of Leicester 
NHS Trust 




94 (80%) 19 (76%) 75 (82%) 52 (83%) 42 (78%) 
Labetalol 47 (40%) 6 (24%) 41 (45%) 25 (40%) 22 (41%) 
Nifedipine 47 (40%) 13 (52%) 34 (37%) 27 (43%) 20 (37%) 
CHT= chronic hypertension, SPE=superimposed preeclampsia, SD= standard deviation, IQR= interquartile 631 
range 632 
*denotes characteristics that are significantly different between the compared subgroups 633 
  634 
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Table 2 Maternal outcomes 635 













Mean blood pressure per 
woman†, mmHg 
median (IQR) 
     
Systolic 
133 
(127 to 137) 
137* 
(131 to 142) 
132 
(127 to 136) 
134 
(127 to 140) 
132 
(128 to 134) 
Diastolic 
84 
(81 to 89) 
87* 
(84 to 93) 
84 
(81 to 88) 
86* 
(82 to 90) 
83 
(81 to 86) 
Incidence of severe 
hypertension‡, days  
number (%)  
     
0 44 (38%) 7 (28%) 37 (40%) 20 (32%) 24 (44%) 
1 30 (26%) 4 (16%) 26 (28%) 14 (22%) 16 (30%) 
2 15 (12%) 1 (4%) 14 (15%) 10 (16%) 5 (9.3%) 
≥3 28 (24%) 13* (52%) 15 (16%) 19 (30%) 9 (17%) 
Superimposed preeclampsia 
number (%) 
25 (21%) 25 (100%) 92 (0%) 9 (14%) 16 (30%) 
Mode of delivery 
number (%) 
     
Spontaneous vaginal delivery 39 (34%) 4 (16%) 35 (39%) 20 (32%) 19 (35%) 
Assisted vaginal delivery 6 (5.2%) 3 (12%) 3 (3.3%) 4 (6.5%) 2 (3.7%) 
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Elective Caesarean section 16 (14%) 2 (8%) 14 (16%) 6 (9.7%) 10 (19%) 
Emergency Caesarean section 54 (47%) 16* (64%) 38 (42%) 32 (52%) 22 (41%) 
Gestation at delivery, weeks 
median (IQR) 
38 
(35.9 to 39) 
34.7* 
(30.3 to 37.9) 
38.3  
(37 to 39.3) 
37.9 
(35.6 to 39) 
38.0 
(36 to 39.4) 
Pre-term birth <37 weeks 
number (%) 
36 (31%) 14* (56%) 22 (24%) 19 (30%) 17 (31%) 
Perinatal outcome 
number (%) 
     
Livebirth 106 (91%) 23 (92%) 83 (91%) 56 (89%) 50 (93%) 
Miscarriage 4 (3.4%) 0 4 (4.3%) 3 (4.8%) 1 (1.9%) 
Termination of pregnancy 3 (2.6%) 1 (4%) 2 (2.2%) 2 (3.2%) 1 (1.9%) 
Stillbirth 4 (3.4%) 1 (4%) 3 (3.2%) 2 (3.2%) 2 (3.7%) 
CHT= chronic hypertension, SPE=superimposed preeclampsia  636 
*denotes outcomes that are significantly different between the compared groups 637 
†Mean blood pressure of all antenatal blood pressures during study participation 638 
‡Severe hypertension= systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥110 mmHg 639 
640 
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Table 3 Perinatal outcomes 641 















(2360 to 3250) 
2270*  
(1320 to 2840) 
3020  
(2690 to 3440) 
2980  
(2520 to 3180) 
2930  
(2560 to 3400) 
Birthweight <10th centile 
number (%) 
31 (29%) 13* (52%) 18 (22%) 17 (30%) 14 (28%) 
Birthweight <3rd centile 
number (%) 
16 (15%) 10* (40%) 6 (7.2%) 9 (16%) 7 (14%) 
Neonatal unit admission 
number (%) 
25 (23%) 12* (52%) 13 (14%) 12 (21%) 13 (26%) 
CHT= chronic hypertension, SPE=superimposed preeclampsia  642 
*denotes outcomes that are significantly different between the compared groups 643 
 644 
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